Syapse provides the N‑Power platform, an always‑on clinical research system that embeds trial enrollment and data collection into routine community oncology practice. It creates prospectively generated external control cohorts matching trial criteria and offers a Community Trial Accelerator that continuously pre‑screens patients, enabling sponsors to access high‑quality real‑world comparator data and accelerate enrollment across diverse populations.
Funding
$35M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Oncologists in community settings lack integrated mechanisms to enroll patients in clinical trials, while pharmaceutical sponsors struggle to access diverse, real‑world patient cohorts for robust trial design and control arms. This disconnect leads to delayed studies and high failure rates in later phases.
Solution
Syapse’s N‑Power platform creates an always‑on clinical research system that embeds trial enrollment and data collection into routine community oncology practice. By building prospective external control cohorts that mirror trial eligibility, imaging schedules, genomic profiling, and biosample timing, the platform supplies sponsors with high‑quality comparator data for phase II and phase III decision making. Simultaneously, the Community Trial Accelerator continuously gathers anticipatory patient data, enabling physicians to identify and discuss trial opportunities at the optimal moment. Real‑time site activation signals allow sponsors to allocate resources only when eligible patients are present, accelerating enrollment and reducing trial delays.
Target Audience
Primary customers are pharmaceutical companies and biotech sponsors seeking real‑world control data and accelerated enrollment, and community oncology practices that want to incorporate clinical research into everyday patient care.
Features
- Prospectively generated external control cohorts with matched inclusion/exclusion criteria, NGS data, prognostic covariates, and standardized imaging and biosample schedules
- Integrated workflow that captures comprehensive patient data during routine oncology visits, turning standard care into research‑ready information
- Automated pre‑screening across entire practice populations to surface every eligible trial participant
- Signal‑based site activation dashboard that notifies sponsors and sites when enrollment‑ready patients are available
- Support for single‑arm studies and augmentation of randomized control arms, reducing the need for separate control groups
- Infrastructure designed to increase representation of under‑served and diverse patient populations in trials